Nasal Antihistamines Market

2016-2020 Nasal Antihistamines Demand Outlook Compared to the 2021-2031 Forecast

Demand for nasal antihistamines grew at a CAGR of 3.2% between 2016 and 2020. Growing prevalence of allergic rhinitis (AR), ease of administration of drugs via nasal route, and the introduction of technologically advanced products are expected to propel sales of nasal antihistamines over the forecast period

New product launches & Food and Drug Administration (FDA) approval for over-the-counter (OTC) switch of prescription-based nasal sprays are projected to offer lucrative opportunities to key market players. Coupled with this, collaboration with local players is expected to help  companies to expand their regional presence as well as product offerings.

Owing to aforementioned factors, FMI expects the global nasal antihistamines market to grow at a CAGR of 4.6%  through 2031.

Download a Comprehensive Report Snapshot

How is Increasing Prevalence of Allergic Rhinitis Affecting Nasal Antihistamines Sales?

According to the American College of Allergy, Asthma and Immunology (ACAAI), allergic rhinitis (AR) has increased by 100% in the last three decades. In the U.S. and Europe, more than 40% of the population is sensitized to some or the other inhalant allergens. Possible reasons for increasing prevalence of AR are intensifying air pollution and increased sensitization to allergens.

According to epidemiological research, the prevalence of AR has risen steadily in more industrialized countries, and it now affects 10%–40% of adults and 2%–25% of children, globally. Similarly, rising tendency of AR has been noted in recent decades, particularly in China due to with rapid urbanization,  westernized lifestyles and shifting food habits.

As a result, demand for nasal antihistamines is projected to rise at a steady pace over the forecast period, opines FMI.

Will High Demand for Over-The-Counter Drugs Influence Sales of Nasal Antihistamines?

Growing demand for generic medical products in developing countries such as India, China, Brazil, Mexico, and South Africa is compelling manufacturers to launch effective and easily accessible nasal sprays and drops.

High demand for these products can be attributed to lower prices and convenient availability through medical and pharmaceutical outlets. Many nasal antihistamine drugs are getting off-patented, which is a great opportunity for the manufacturers to launch innovative and advanced nasal antihistamines in the market.

Besides this, increasing incidence of respiratory diseases including asthma, chronoic obstructive pulmonary disease (COPD), and allergic rhinitis is expected to provide impetus to growth of the market.

Besides this, investments in research and development by pharmaceutical companies, government initiatives to spread awareness regarding common health dfisorders, along with advancements in the healthcare infrastructure in various countries will continue propelling sales of nasal antihistamines over the forecast period.

What is the Impact of the COVID-19 Crisis on the Market?

The COVID-19 pandemic is has had a moderately positive impact on the nasal antihistamines market as the nasal mode of administration gained significance during disease progression. However, closed transnational borders, lengthy customs procedures, choked distribution channels and limited stock of supplies impacted sales of nasal antihistamines to an extent.

Since nasal sprays are gaining importance in the treatment of COVID-19, the market is anticipated to recover over the forecast period, opines FMI. Growth can be attributed to ease of nasal administration and increasing adoption of self-medication during the lockdown period. These trends are anticipated to continue over the forecast period, shaping the demand outlook of nasal antihistamines positively.

Country-wise Insights

What is the Demand Outlook for Nasal Antihistamines in the U.S.?

In 2021, the U.S. is estimated to account for 90.7% of the North America nasal antihistamines market share. The dominance is driven due to growing prevalence of allergic rhinitis cases in the pediatric population. In the year 2020, it was estimated that around 21.1% of the pediatric population suffered from allergic rhinitis. Along with this increasing adoption of nasal sprays, and the presence of a well-developed healthcare infrastructure in the U.S. will continue pushing sales of nasal antihistamines over the assessment period.

Why is the U.K. Considered a Lucrative Nasal Antihistamines Market?

The U.K. is projected to account for over 17.9% of the Europe nasal antihistamine market 2021. Rising demand for nasal antihistamines in the U.K. can be attributed to new product launches, collaborations among key market players, technological advancements in the healthcare sector, and growing awareness of the benefits of nasal antihistamines in treating allergic rhinitis effectively.

How Will Nasal Antihistamines Sales Fare Across China?  

Sales of nasal antihistamines in China are expected to grow at a 6.5% CAGR in the East Asia region throughout the forecast period. In China, increasing per capita expenditure on healthcare, favorable government policies, new product launches, and growing funding for life science research are anticipated to augment the growth of the nasal antihistamine market in the forthcoming years.

Will India Continue Registering High Demand for Nasal Antihistamines?

In 2020, India accounted for 46.3% of the total South Asia nasal antihistamines market. Consumers in India are increasingly adopting nasal antihistamine therapy for the treatment of allergic rhinitis. Along with this, new product launches in the country at comparatively lower costs is anticipated to provide growth opportunities to key market players.

Since most of the population in India relies on out-of-pocket expenditure for healthcare, generic products are preferred for being cost-efficient. The aforementioned factors are expected to push sales of nasal antihistamines in India over the assessment period.

Category-wise Insights

Demand for Nasal Sprays to Remain High

In terms of product, the nasal sprays segment will continue to hold a dominant share of neartly 90% of the global nasal antihistamines market in 2021.

Maximum Sales of Nasal Antihistamines to be Recorded Among Adults

In terms of age group, the adult group of patients will account for over half of the market share in 2021. This trend is expected to continue during the forecast period as well.   

Sales of Nasal Antihistamines Through Retail Pharmacies to Gain Traction

Based on distribution channels, the retail pharmacies segment is projected to account for more than 40% of the nasal antihistamines market share in 2021, with sales growing at a 4.4% CAGR over the forecast period.

Competitive Landscape

The market is consolidated and is dominated by players such as Bayer Healthcare, Novartis AG, Glenmark Pharmaceuticals, GlaxoSmithKline, Cipla, Merck & Co., Sun Pharmaceuticals, Viatris (Meda Pharmaceuticals), Proctor & Gamble, Ascend Laboratories (Alkem Laboratories), Centaur Pharmaceuticals, J pharmaceuticals, Sato Pharmaceuticals, and Altair Pharmaceuticals.

Manufacturers in the nasal antihistamines market are aiming to launch new products in the market to expand their product portfolios. Apart from this, strategic collaborations, mergers and acquisitions are expected to remain lucrative growth strategies adopted by key players through 2031. For instance:

• In May 2021, Glenmark Pharma launched a nasal spray called Ryaltris in India. Glenmark is one of the market leaders in the respiratory segment and was the first to introduce the branded version at an affordable price in India.
• In June 2021, FDA approved the use of Bayer AG’s Astepro, which is used for seasonal and perineal allergies, for non-prescription use through a process called a partial prescription to nonprescription switch. This FDA approval has led to individuals having the accessibility of a safe and effective nasal antihistamine without requiring the assistance of a healthcare provider.

In July 2019, Mylan N.V. and Pfizer Inc. signed a definitive agreement to merge Mylan with Upjohn, Pfizer's off-patent branded and generic established pharmaceuticals business, to become Viatris Inc., a new global pharmaceutical corporation.

• In December 2018, Procter & Gamble (P&G) completed the acquisition of Merck’s Consumer Health business in a €3.4bn ($3.8bn) deal. It is intended to improve P&G’s over the counter (OTC) geographic scale brand portfolio and category footprint across 15 markets.

Some of the leading companies operating in the market are:

• Bayer Healthcare LLC
• Novartis AG
• Glenmark Pharmaceuticals
• GlaxoSmithKline
• Sun Pharmaceuticals
• Cipla
• Merck & Co.
• Viatris (Meda Pharmaceuticals)
• Proctor & Gamble
• Ascend Laboratories LLC (Alkem Laboratories)
• Centaur Pharmaceuticals
• J Pharmaceuticals
• Alitair Pharmaceuticals
• Sato Pharmaceuticals

Scope of Report

Key Questions Answered in the Report

• What is the current Nasal Antihistamines Market value?

  The global Nasal Antihistamines Market is projected to reach US$ 1.9 Bn in 2021. 

• At what rate did the global nasal antihistamines market grow between 2016 and 2020?

  The global market grew at a sluggish 3.2% CAGR between 2016 and 2020.

• What are the key trends driving sales of nasal antihistamines?

  Increasing prevalence of allergic rhinitis (AR), along with introduction of affordable over-the-counter products for nasal treatment are anticipated to continue driving sales of nasal anthistamines over the assessment period.

• Who are the leading players in the global nasal antihistamines market?

  Some of the leading companies offering nasal antihistamines are Bayer Healthcare LLC, Novartis AG, Glenmark Pharmaceuticals, GlaxoSmithKline, Sun Pharmaceuticals, Cipla, Merck & Co, Viatris (Meda Pharmaceuticals), Proctor & Gamble, Ascend Laboratories LLC (Alkem Laboratories), Centaur Pharmaceuticals, J Pharmaceuticals, Alitair Pharmaceuticals and Sato Pharmaceuticals.

• What will be the demand outlook for North America nasal antihistamines market?

  Demand for nasal antihistamines in North America is expected to rise at a 3.1% CAGR through 2031.

• What will be the nasal antihistamines market share in Europe?

  Europe is expected to account for 13.9% of the global market share in 2031.

• Which are the top 5 countries driving demand for nasal antihistamines?

  China, U.S., India, Brazil and Japan are the top 5 countries that are driving the demand for nasal antihistamines.

• What is the current market share of Japan and South Korea in the global nasal antihistamines market?

  Sales of nasal antihistamines in Japan and South Korea are projected to grow at 5.3% and 3.8% CAGR respectively through 2031.

Nasal antihistamines by Category

Product:

• Nasal Spray
• Nasal Drops

Age Group:

• Adult
• Pediatric

Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Stores

Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa (MEA)